Prof. Hüseyin FIRAT
President & CEO
He is a pediatrician and practiced as an associate professor in Paris University hospitals. After his PhD of Immunology at Pasteur Institute, he was accredited as research director, responsible of the Immunology Laboratory at Généthon. In 2002, he joined then the Biomarker Department of Novartis Pharma, where he headed global omics data analysis sections worldwide, served as senior Biomarker Expert in International Project Teams and was member of Novartis Pharma Innovation Team, Basel. His research activities generated several patented discoveries, based on which three biotech companies have been created. In 2007, he has been accredited as University Professor in France and founded Firalis SAS. He is the CEO and CSO of the company since then.
Thierry Guyon, PhD in Cellular and Molecular Biology
CSO and Head of laboratories
Thierry joined the company in October 2009 as head of laboratories and R&D programs. He studied at the University of Paris (Paris VI) and holds a master degree in biochemistry and a Ph.D. in Cellular and Molecular Biology. He has a 14 years experience in pharmaceutical and biotechnology industries. After several years as researcher at Pfizer, Thierry was R&D Manager for 8 years at Nautilus Biotech, a biotechnology company dedicated to the optimisation of next-generation therapeutic proteins with superior pharmacological profiles and suitable for oral administration. He was in charge of protein engineering, screening and preclinical studies. He also participated in the clinical development of several new proteins. He is the author of 9 publications and 8 patents.
Alain Razafindratsita, PharmD
Expert in monoclonal antibodies and Head of in vivo studies department
Alain obtained his doctorate of pharmacy (PharmD) from the University of Toulouse; he is also graduated of the University of Nancy and was immunology researcher at the Institut Gustave Roussy. He has over 10 years of experience in the pharmaceutical industry. He worked as Director of monoclonal antibodies department in the Merck Group. Subsequently he was responsible for the biological evaluation in Novagali Pharma, a biotechnology company dedicated to new drug formulations in the field of ophthalmology. He was appointed Director of Preclinical studies in Stallergenes SA before he joined the company in 2007. He is the author of 9 publications and 5 patents.